Casi 5 años teniendo controlada la esclerosis múltiple con Fingolimod, en el último año con 1 pastilla cada 48 horas.
Más de 800 euros cada caja de 28 pastillas, del genérico.
Siempre Sanidad Pública.
Más de 800 euros cada caja de 28 pastillas, del genérico.
Siempre Sanidad Pública.
November 6, 2025 at 11:43 AM
Casi 5 años teniendo controlada la esclerosis múltiple con Fingolimod, en el último año con 1 pastilla cada 48 horas.
Más de 800 euros cada caja de 28 pastillas, del genérico.
Siempre Sanidad Pública.
Más de 800 euros cada caja de 28 pastillas, del genérico.
Siempre Sanidad Pública.
📍Tayfun Kahraman’ın sol bacağında güç kaybı ve uyuşma var, bu artık kırmızı alarm, MS atağının ciddi olduğuna işaret ediyor!
📍Fingolimod başlanmış, bu ilaç ataklar ağırlaştığında, ilerleme riski ...+
📍Fingolimod başlanmış, bu ilaç ataklar ağırlaştığında, ilerleme riski ...+
December 26, 2025 at 7:58 AM
📍Tayfun Kahraman’ın sol bacağında güç kaybı ve uyuşma var, bu artık kırmızı alarm, MS atağının ciddi olduğuna işaret ediyor!
📍Fingolimod başlanmış, bu ilaç ataklar ağırlaştığında, ilerleme riski ...+
📍Fingolimod başlanmış, bu ilaç ataklar ağırlaştığında, ilerleme riski ...+
Yesterday I took my (I hope) final fingolimod pill for MS. My neurologist says he’s had great success weaning people (with five years of no relapses or new MRI activity) off of their MS medications once they turn 55.
My wife said I’m a good swallower, which, uh…
My wife said I’m a good swallower, which, uh…
August 19, 2026 at 2:40 PM
Yesterday I took my (I hope) final fingolimod pill for MS. My neurologist says he’s had great success weaning people (with five years of no relapses or new MRI activity) off of their MS medications once they turn 55.
My wife said I’m a good swallower, which, uh…
My wife said I’m a good swallower, which, uh…
They out here giving drugs Silmarillion-ass names
January 14, 2025 at 3:57 PM
They out here giving drugs Silmarillion-ass names
NIH-funded basic research allowed me to discover two molecules (COX-2 and S1PR1) that became drug targets - COX-2 inhibitors and S1PR modulators - more than 7 million prescriptions for Celebrex taken for pain; >350k people have taken Fingolimod/Ozanimod for MS and IBD/UC-basic research is essential!
9 Federally Funded Scientific Breakthroughs That Changed Everything www.nytimes.com/2025/05/16/s...
9 Federally Funded Scientific Breakthroughs That Changed Everything
www.nytimes.com
May 16, 2025 at 12:14 PM
NIH-funded basic research allowed me to discover two molecules (COX-2 and S1PR1) that became drug targets - COX-2 inhibitors and S1PR modulators - more than 7 million prescriptions for Celebrex taken for pain; >350k people have taken Fingolimod/Ozanimod for MS and IBD/UC-basic research is essential!
Same here: read the alt!
September 24, 2026 at 2:00 PM
Same here: read the alt!
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
patienttalk.org/rituximab-is...
patienttalk.org/rituximab-is...
March 1, 2025 at 11:38 AM
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
patienttalk.org/rituximab-is...
patienttalk.org/rituximab-is...
Both fingolimod and ocrelizumab are FDA approved for treatment in adult multiple sclerosis. Only fingolimod is approved for treatment in POMS. This retrospective study explores the safety and efficacy of fingolimod & ocrelizumab in treatment of POMS
🔗 buff.ly/i9f90pA
🔗 buff.ly/i9f90pA
March 15, 2025 at 3:23 PM
Both fingolimod and ocrelizumab are FDA approved for treatment in adult multiple sclerosis. Only fingolimod is approved for treatment in POMS. This retrospective study explores the safety and efficacy of fingolimod & ocrelizumab in treatment of POMS
🔗 buff.ly/i9f90pA
🔗 buff.ly/i9f90pA
#MS_Selfie Q&A 73: Ocrelizumab vs. Ofatumumab vs. Ublituximab
The other choice is to stay on fingolimod and see what happens over the next 6-12 months. Do you relate to this patient's dilemma? =>
The other choice is to stay on fingolimod and see what happens over the next 6-12 months. Do you relate to this patient's dilemma? =>
Q&A 73: Ocrelizumab vs. Ofatumumab vs. Ublituximab
The other choice is to stay on fingolimod and see what happens over the next 6-12 months.
buff.ly
February 11, 2025 at 3:35 AM
#MS_Selfie Q&A 73: Ocrelizumab vs. Ofatumumab vs. Ublituximab
The other choice is to stay on fingolimod and see what happens over the next 6-12 months. Do you relate to this patient's dilemma? =>
The other choice is to stay on fingolimod and see what happens over the next 6-12 months. Do you relate to this patient's dilemma? =>
Ah, who could forget Fingolimod and his legendary battle with Acëtaminophîn.
January 14, 2025 at 4:34 PM
Ah, who could forget Fingolimod and his legendary battle with Acëtaminophîn.
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
December 10, 2024 at 12:55 AM
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#PubSaludMurcia
Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells
@AreaUnoArrixaca @IMIB_RMurcia @CarlosEGalera
👉 https://dx.plos.org/10.1371/journal.ppat.1014266
Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells
@AreaUnoArrixaca @IMIB_RMurcia @CarlosEGalera
👉 https://dx.plos.org/10.1371/journal.ppat.1014266
June 8, 2026 at 12:03 PM
#PubSaludMurcia
Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells
@AreaUnoArrixaca @IMIB_RMurcia @CarlosEGalera
👉 https://dx.plos.org/10.1371/journal.ppat.1014266
Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells
@AreaUnoArrixaca @IMIB_RMurcia @CarlosEGalera
👉 https://dx.plos.org/10.1371/journal.ppat.1014266
"...over 80% of patients with #MultipleSclerosis who abruptly stopped #fingolimod therapy experienced disease #relapse and increased disease activity. To avoid disease relapse, our study suggests using gradual tapering with a short #washout when discontinuing fingolimod."
doi.org/10.7224/1537...
doi.org/10.7224/1537...
December 23, 2025 at 2:31 PM
"...over 80% of patients with #MultipleSclerosis who abruptly stopped #fingolimod therapy experienced disease #relapse and increased disease activity. To avoid disease relapse, our study suggests using gradual tapering with a short #washout when discontinuing fingolimod."
doi.org/10.7224/1537...
doi.org/10.7224/1537...
Multiple sclerosis involves misdirected immune activity, and Gilenya was one of the first therapies to change how those immune cells move. It works by redirecting lymphocytes rather than eliminating them. Explore the full breakdown in my new video.
youtu.be/DPLKBcbdz2k
youtu.be/DPLKBcbdz2k
How does Gilenya (Fingolimod) Work for MS?
YouTube video by Dr. Rob Swanda
youtu.be
September 22, 2026 at 8:37 PM
Multiple sclerosis involves misdirected immune activity, and Gilenya was one of the first therapies to change how those immune cells move. It works by redirecting lymphocytes rather than eliminating them. Explore the full breakdown in my new video.
youtu.be/DPLKBcbdz2k
youtu.be/DPLKBcbdz2k
United Health care formulary for multiple sclerosis. It seems only fingolimod (generic gilenya) is tier 1. Would anyone care to share experiences with UHC with MS drugs?https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/pharmacy-pdl-3t-adv-may-2024.pdf
December 20, 2024 at 6:18 AM
United Health care formulary for multiple sclerosis. It seems only fingolimod (generic gilenya) is tier 1. Would anyone care to share experiences with UHC with MS drugs?https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/pharmacy-pdl-3t-adv-may-2024.pdf
Should dosing of gilenya be weight or monitoring based? Despite a set dose of 0.5 mg once daily, levels of the active metabolite fingolimod phosphate ranged nearly 10 fold from 0.48 to 4.28 µg/L in this study, and it correlated with lymphocyte count. www.msard-journal.com/article/S221...
Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis
Multiple sclerosis (MS) is an immune-mediated disease characterised by inflammation, demyelination, and degenerative changes in the central nervous system (CNS) (Galetta and Bhattacharyya, 2019). The disease course can vary among patients, with the most common form being relapsing-remitting MS (RRMS), which is characterised by clearly defined relapses of new or worsening neurological symptoms. MS is one of the most common causes of neurological disability in young adults aged between 20 and 40 years, with approximately two-thirds of cases occurring in women (Hauser and Cree, 2020; Dobson and Giovannoni, 2019; Oh et al., 2018; Karussis, 2014).
www.msard-journal.com
December 29, 2024 at 5:29 PM
Should dosing of gilenya be weight or monitoring based? Despite a set dose of 0.5 mg once daily, levels of the active metabolite fingolimod phosphate ranged nearly 10 fold from 0.48 to 4.28 µg/L in this study, and it correlated with lymphocyte count. www.msard-journal.com/article/S221...
Believe it or not, at least one good thing came from a Cordyceps: fingolimod, a therapy for #MS. (Derived from Isaria sinclairii, the anamorph form of Cordyceps sinclairii.)
December 13, 2025 at 9:54 PM
Believe it or not, at least one good thing came from a Cordyceps: fingolimod, a therapy for #MS. (Derived from Isaria sinclairii, the anamorph form of Cordyceps sinclairii.)
July 31, 2025 at 9:36 PM
MS rebound disease can occur very quickly after stopping gilenya. Here is a case report of a 15 year old boy who developed a severe flare affecting cognition, balance, and vision 4 weeks after stopping gilenya (who had planned to switch to ocrevus) www.thieme-connect.de/products/ejo...
Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review
Thieme E-Books & E-Journals
www.thieme-connect.de
March 11, 2025 at 11:47 PM
MS rebound disease can occur very quickly after stopping gilenya. Here is a case report of a 15 year old boy who developed a severe flare affecting cognition, balance, and vision 4 weeks after stopping gilenya (who had planned to switch to ocrevus) www.thieme-connect.de/products/ejo...
Státní ústav pro kontrolu léčiv (SÚKL) dočasně pozastavil distribuci a výdej vybraných šarží čtyř léčivých přípravků. Důvodem je prověření možné závady v jejich kvalitě. Opatření se týká léků Atominex, Fingolimod Zentiva, Deferasirox Zentiva a Helicid Neo.
July 28, 2026 at 3:12 PM
Státní ústav pro kontrolu léčiv (SÚKL) dočasně pozastavil distribuci a výdej vybraných šarží čtyř léčivých přípravků. Důvodem je prověření možné závady v jejich kvalitě. Opatření se týká léků Atominex, Fingolimod Zentiva, Deferasirox Zentiva a Helicid Neo.
🧪 #Amiselimod demonstrated a more favourable cardiac safety profile than fingolimod over 28-day administration.
🧪Unlike fingolimod, there were no clinically relevant cardiac adverse effects observed with amiselimod at doses up to 0.8 mg. Dose titration was not necessary.
🧪Unlike fingolimod, there were no clinically relevant cardiac adverse effects observed with amiselimod at doses up to 0.8 mg. Dose titration was not necessary.
November 4, 2024 at 12:00 PM
🧪 #Amiselimod demonstrated a more favourable cardiac safety profile than fingolimod over 28-day administration.
🧪Unlike fingolimod, there were no clinically relevant cardiac adverse effects observed with amiselimod at doses up to 0.8 mg. Dose titration was not necessary.
🧪Unlike fingolimod, there were no clinically relevant cardiac adverse effects observed with amiselimod at doses up to 0.8 mg. Dose titration was not necessary.
Convincing evidence of true remyelination could only be found in preclinical studies investigating glatiramer acetate, teriflunomide, Fingolimod, Siponimod, Ponesimod, and alemtuzumab.
December 13, 2025 at 10:00 AM
Convincing evidence of true remyelination could only be found in preclinical studies investigating glatiramer acetate, teriflunomide, Fingolimod, Siponimod, Ponesimod, and alemtuzumab.
RS bych měl, ale beru Gilenya (Fingolimod), což je také lék "druhé linie".
October 25, 2023 at 5:57 AM
RS bych měl, ale beru Gilenya (Fingolimod), což je také lék "druhé linie".
December 29, 2024 at 3:04 PM